IsoPlexis is dedicated to accelerating the fight against cancer and a range of our toughest diseases by producing the world’s most precise, award-winning detection systems. By revealing unique immune biomarkers in small subsets of cells, we are advancing immunotherapies and targeted therapies to a more highly precise & personalized stage.
Minimum 15 minutes delayed.
Data Provided by Refinitiv.
Sean Mackay co-founded and leads IsoPlexis as CEO. IsoPlexis’ mission is to provide widely accessible cellular proteomics to speed personalized, curative medicines. The company focuses on shifting paradigms in cell and gene therapy, cancer immunology, and infectious disease towards more patient specific, long lasting treatments. IsoPlexis’ easy to use instrumentation and software have won numerous awards and are used globally to advance precision medicine.
Previously, Sean helped incubate Kleiner Perkins-backed Lifesquare, which connected patients, payers, and providers through sharing essential healthcare information. Additionally, through work at Lazard and with several early-stage ventures, he developed a passion for helping life sciences and medical device companies manage in times of strategic change, to deliver their highly needed products to the clinical ecosystem. Sean has co-authored a number of publications centered around immune medicines and holds patents for a number of single-cell products worldwide.
John co-founded Gilliam Capital LLC, a life science investment firm, and is a member of Launchpad Venture Group in Boston. He is a board member for three healthcare startups and works with a variety of social enterprises. He is currently the Chief Operating Officer of Entrepreneurship for All, a nonprofit that is accelerating economic and social impact through fostering entrepreneurship in mid-sized cities. He was a co-founder of the RNA interference therapeutics company Alnylam Pharmaceuticals where he held the position of Vice President, Strategy and Finance and CFO through to its successful 2004 IPO. He was Vice President of Business Development at Transkaryotic Therapies through to its acquisition by Shire Pharmaceuticals. Over ten years at Biogen he served in several marketing, business development, sales and finance positions, including Country Manager – United Kingdom and Ireland, and Treasurer. He was a Manager at the strategy-consulting firm of Bain & Company. John graduated with a BS in Economics from the University of Pennsylvania’s Wharton School and an MBA from the Yale School of Management. He was a 2014 Fellow in the Advanced Leadership Initiative at Harvard University.
Greg has served as the President of Spring Mountain Capital since its founding in June 2001. Previously, he was a Principal and Chief Financial Officer of McKinsey & Company, Inc. During his 16 years with McKinsey, he led the financial and tax planning for the firm and its worldwide partner group, as well as the identification, evaluation, and selection of traditional and alternative asset managers for over $1 billion of assets in its qualified employee plans and in-house investment office. Greg was also a Trustee of McKinsey’s Profit-Sharing Retirement Plan and a member of the firm’s Investment Committee. After leaving McKinsey in 1998 and prior to joining SMC, Greg was a private investor and consultant. Prior to joining McKinsey, he was associated with the law firm of Donovan Leisure Newton & Irvine. Greg is currently a member of the Advisory Council of the Yale Entrepreneurship Institute and a member of the Investor Board of Venture for America. He received a J.D. from Columbia Law School and a B.S., with honors, in Administrative Science from Yale College. He is a member of the New York Bar and the California Bar.
Dan serves as a Managing Director of Investments at Connecticut Innovations and is an active board member of multiple life sciences companies. Dan contributes to CI’s expertise in biotech with more than 10 years in the industry. He was previously employed by CuraGen Corporation, where he held a variety of scientific and operational management positions. He holds an M.B.A. and M.H.S. degree in Biomedical Sciences from Quinnipiac University, and a B.S. degree in Biology from the University of Dayton.
BOARD DIRECTOR AND SCIENTIFIC ADVISORY BOARD MEMBER
Jim is the Elizabeth W. Gilloon Professor and Professor of Chemistry at Caltech, and Professor of Molecular & Medical Pharmacology at the University of California, Los Angeles (UCLA), and Director of the National Cancer Institute’s NSB Cancer Center. He has founded or co-founded several companies, including NanoSys, MTI, Sofie Biosciences, and Indi Dx, and has served on the board of a number of organizations including the Board of Scientific Advisors of the National Cancer Institute. Jim graduated with a degree in Chemistry from Baylor University in Texas. He completed his Ph.D. in Physics and Chemistry from Rice University. He was awarded the 2000 Feynman Prize in Nanotechnology. He became a fellow of American Physical Society in 1999 and in 2009 he was named one of the seven most powerful innovators of the world by Forbes magazine.